KRAS and cancer: Several therapeutic approaches that target inflammation and immune modulation specifically in KRAS-mutant cancers have been undergoing investigation in clinical trials (Table 1), despite the fact that a larger number of trials have been studying these effects in different cancers often driven by KRAS mutations, regardless of the mutation status (Table 2).